Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 14/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ADK | P55263 | 1/20 | 0.41 |
| ▸ | DBH | P09172 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3817538 | 0.87 | SLC29A1 (0.47) | SLC29A1KMT2AMEN1LMNAADK | |
| SCHEMBL18342054 | 0.80 | MEN1 (0.51) | SLC29A1KMT2AMEN1ADK | |
| SCHEMBL15708559 | 0.80 | CA12 (0.44) | SLC29A1KMT2AMEN1ADKMAPT | |
| SCHEMBL16236981 | 0.74 | KDM4C (0.41) | SLC29A1KMT2AMEN1LMNAADK | |
| SCHEMBL4014438 | 0.72 | ADK (0.43) | SLC29A1KMT2AMEN1ADK | |
| SCHEMBL7701985 | 0.72 | SLC29A1 (0.44) | SLC29A1KMT2AMEN1LMNAADK | |
| SCHEMBL7704315 | 0.72 | SLC29A1 (0.44) | SLC29A1KMT2AMEN1LMNAADK | |
| SCHEMBL14617855 | 0.71 | FGFR1 (0.47) | KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL29503417 | 0.71 | ADK (0.46) | SLC29A1KMT2AMEN1ADK | |
| SCHEMBL16236999 | 0.71 | ADK (0.46) | SLC29A1KMT2AMEN1ADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730148-A4 | AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS | ABBOTT LAB (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-1730148-A2 | AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS | Abbott Laboratories (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20060025383-A1 | Aminobenzoxazoles as therapeutic agents | ABBOTT LABORATORIES | 2006-02-02 | — | — | US | disclosed |
| WO-2005074603-A2 | AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025383-A1 | Aminobenzoxazoles as therapeutic agents | ABL1, MAP3K19, MAP3K20 | SLC29A1 1901/4885KMT2A 261/4885MEN1 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.